DYB186: Oral drug for cholesterol elimination and reduction of atherosclerosis

Development stage: Proof of concept/Lead optimization.

The goal of the therapy is to stimulate the body to produce more ApoA1 which leads to cholesterol elimination and reduction of atherosclerosis.

The lead compound in this program was shown to increase ApoA1 expression and cholesterol elimination after oral administration in a transgenic animal model expressing human apoA1.

The use of the drug class is covered by granted US and EU patents. The development candidates are protected by additional patents.